DURECT Corporation (DRRX)
NASDAQ: DRRX · Real-Time Price · USD
1.835
-0.035 (-1.87%)
At close: Aug 1, 2025, 4:00 PM
1.830
-0.005 (-0.26%)
After-hours: Aug 1, 2025, 7:55 PM EDT
Accolade Revenue
DURECT had revenue of $321.00K in the quarter ending March 31, 2025, a decrease of -35.28%. This brings the company's revenue in the last twelve months to $1.86M, up 79.84% year-over-year. In the year 2024, DURECT had annual revenue of $2.03M, down -21.58%.
Revenue (ttm)
$1.86M
Revenue Growth
+79.84%
P/S Ratio
30.69
Revenue / Employee
$88,381
Employees
21
Market Cap
56.96M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.03M | -559.00K | -21.58% |
Dec 31, 2023 | 2.59M | -16.69M | -86.57% |
Dec 31, 2022 | 19.28M | 5.31M | 37.96% |
Dec 31, 2021 | 13.98M | -16.13M | -53.58% |
Dec 31, 2020 | 30.11M | 5.04M | 20.09% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
DRRX News
- 3 days ago - Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout - Benzinga
- 4 days ago - Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease - Accesswire
- 2 months ago - DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update - PRNewsWire
- 4 months ago - DURECT Corporation (DRRX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - PRNewsWire
- 4 months ago - DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update - PRNewsWire
- 6 months ago - DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - PRNewsWire
- 6 months ago - DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence - PRNewsWire